MA5-21012
antibody from Invitrogen Antibodies
Targeting: CLEC4M
CD209L, CD299, DC-SIGN2, DC-SIGNR, DCSIGNR, HP10347, LSIGN
Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-21012 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD299 (DC-SIGN/L) Monoclonal Antibody (2G1)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- Peptide Sequence: SQRNWHDSVT ACQEVRAQLV VIKTAEEQNF LQLQTSRSNR FSWMGLSDLN QEGTWQWVDG SPLSPSFQRY WNSGEPNNSG NEDCAEFSGS GWNDNRCDVD NYWICKKPAA
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 2G1
- Vial size
- 100 µg
- Concentration
- 1.0 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Monitoring Viral Entry in Real-Time Using a Luciferase Recombinant Vesicular Stomatitis Virus Producing SARS-CoV-2, EBOV, LASV, CHIKV, and VSV Glycoproteins.
Lay Mendoza MF, Acciani MD, Levit CN, Santa Maria C, Brindley MA
Viruses 2020 Dec 17;12(12)
Viruses 2020 Dec 17;12(12)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 rVSVG/EBOV entry kinetics: ( A ) VeroS cells were infected with rVSVG/EBOV at multiple MOIs, inoculum was removed after 1 h, and monitored for luciferase production over time. ( B ) VeroS, HEK293T, and HAP1 cells were infected with rVSVG/EBOV (MOI 1), inoculum was not removed, and monitored for luciferase production over time. Right panel zooms in to display the signals observed in HAP1 and HEK293T cells. ( C ) Immunoblots demonstrating production of the transfected receptors in HEK293T cells. ( D ) HEK293T cells transfected with the indicated receptors were infected with rVSVG/EBOV and monitored for luciferase production over time. Each experiment was repeated in duplicate, three independent times. Data shown are the averages of averages and corresponding SEM of three independent trials.